Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)

Launched by ISTITUTO ROMAGNOLO PER LO STUDIO DEI TUMORI DINO AMADORI IRST S.R.L. IRCCS · Mar 5, 2020

Keywords

ClinConnect Summary

This clinical trial is studying Diffuse Large B-cell Lymphoma (DLBCL), a type of cancer that affects the lymphatic system. The goal is to find new markers, called biomarkers, that can help predict how well patients will respond to treatment and how long they might live without their cancer getting worse. Researchers will look at different samples from patients, including blood and tissue, to understand the cancer better and identify factors that may influence treatment outcomes.

To be eligible for the study, participants should be newly diagnosed with high-grade DLBCL and starting their first standard treatment. They need to provide written consent and have a sample of their tumor available. If you decide to join, you can expect to undergo some tests to analyze the characteristics of your cancer, which will help researchers learn more about how to treat DLBCL in the future. Importantly, patients currently enrolled in other clinical trials cannot participate in this study. The trial is currently recruiting participants and is open to individuals of all genders aged 65 and older.

Gender

ALL

Eligibility criteria

• Inclusion Criteria for the prospective cohort:
• • New diagnosis of High grade Diffuse large B cell Lymphoma undergoing first line standard treatment;
• • Signed written informed consent;
• • Availability of FFPE sample.
• Inclusion Criteria for the retrospective cohort:
• • Diagnosis of High grade Diffuse large B cell Lymphoma from 2011 to 2017;
• • Availability of FFPE sample and clinical data.
• Exclusion Criteria:
• • Patients included in clinical trials.